Market open
Compass Therapeutics/$CMPX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
Ticker
$CMPX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
Website
CMPX Metrics
BasicAdvanced
$208M
Market cap
-
P/E ratio
-$0.35
EPS
0.75
Beta
-
Dividend rate
Price and volume
Market cap
$208M
Beta
0.75
52-week high
$2.34
52-week low
$0.77
Average daily volume
525K
Financial strength
Current ratio
31.838
Quick ratio
30.544
Long term debt to equity
4.567
Total debt to equity
4.969
Management effectiveness
Return on assets (TTM)
-21.71%
Return on equity (TTM)
-32.00%
Valuation
Price to revenue (TTM)
240.102
Price to book
1.5
Price to tangible book (TTM)
1.5
Price to free cash flow (TTM)
-4.243
Growth
Earnings per share change (TTM)
8.50%
3-year earnings per share growth (CAGR)
-37.28%
What the Analysts think about CMPX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
CMPX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CMPX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CMPX News
AllArticlesVideos
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
GlobeNewsWire·3 days ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer
Seeking Alpha·4 days ago
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Compass Therapeutics stock?
Compass Therapeutics (CMPX) has a market cap of $208M as of December 13, 2024.
What is the P/E ratio for Compass Therapeutics stock?
The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of December 13, 2024.
Does Compass Therapeutics stock pay dividends?
No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Compass Therapeutics dividend payment date?
Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Therapeutics?
Compass Therapeutics (CMPX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.